Eli Lilly and Company (NYSE:LLY) Trading Up 3.7% – Time to Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price shot up 3.7% on Tuesday . The company traded as high as $1,228.47 and last traded at $1,227.1070. Approximately 2,446,088 shares traded hands during mid-day trading, a decline of 21% from the average daily volume of 3,097,944 shares. The stock had previously closed at $1,183.16.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity-pill momentum: Lilly is reportedly narrowing Novo Nordisk’s early lead in the oral weight-loss market. Investor enthusiasm is being supported by expectations that Lilly’s obesity portfolio can extend its leadership beyond injectable GLP-1 treatments. Eli Lilly, Stock Of The Day, Is Erasing Novo’s Early Lead In Weight-Loss Pills
• Positive Sentiment: Retatrutide progress: Positive trial developments for retatrutide, Lilly’s next-generation obesity and metabolic-disease candidate, have prompted the company to lift related guidance. The drug could strengthen Lilly’s long-term growth outlook if late-stage results and regulatory progress remain favorable. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
• Positive Sentiment: Pipeline expansion through licensing: Lilly entered a global collaboration with OmniAb for an ion-channel discovery program. The agreement, which includes potential milestone payments of up to $370 million, adds another avenue for future drug development and demonstrates continued investment in external innovation. OmniAb Enters Global Collaboration and License Agreement With Eli Lilly
• Positive Sentiment: CNS pipeline transaction: Lilly paid AlzeCure a $10 million upfront amount in an initial transaction involving small-molecule candidates for Alzheimer’s disease and pain, broadening Lilly’s pipeline beyond its core diabetes and obesity franchises. AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction With Lilly
• Neutral Sentiment: Lilly appointed Tayllit Aherdan to oversee operations in the United Arab Emirates, Qatar and Kuwait. The move supports regional execution but is unlikely to materially affect near-term earnings. Lilly Appoints Tayllit Aherdan
• Negative Sentiment: Analysts continue to flag Lilly’s elevated valuation, competition from Novo Nordisk and other obesity-drug developers, and potential pricing and patent pressures. With shares having already delivered substantial long-term gains, strong future growth may be required to justify additional upside. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Bank of America raised their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Leerink Partners boosted their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Up 3.7%

The company has a market cap of $1.16 trillion, a PE ratio of 41.18, a P/E/G ratio of 1.39 and a beta of 0.51. The business has a 50-day simple moving average of $1,171.52 and a 200-day simple moving average of $1,053.72. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Iams Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $754,000. Generali Investments Management Co LLC increased its position in Eli Lilly and Company by 17.5% in the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock valued at $12,258,000 after acquiring an additional 1,521 shares during the period. Amundi increased its stake in shares of Eli Lilly and Company by 9.9% during the first quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after acquiring an additional 454,549 shares during the period. Whitener Capital Management Inc. lifted its holdings in Eli Lilly and Company by 79.3% in the 2nd quarter. Whitener Capital Management Inc. now owns 2,960 shares of the company’s stock valued at $3,550,000 after acquiring an additional 1,309 shares during the last quarter. Finally, May Hill Capital LLC boosted its position in shares of Eli Lilly and Company by 131.6% in the 4th quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock valued at $3,408,000 after purchasing an additional 1,801 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.